VYNE Therapeutics (VYNE) Short Interest Ratio & Short Volume $0.35 +0.00 (+0.26%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$0.35 +0.00 (+0.06%) As of 08/15/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE Therapeutics Short Interest DataVYNE Therapeutics (VYNE) has a short interest of 2.09 million shares, representing 15.33% of the float (the number of shares available for trading by the public). This marks a 526.69% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.2, indicating that it would take 1.2 days of the average trading volume of 3.96 million shares to cover all short positions.Current Short Interest2,090,000 sharesPrevious Short Interest333,500 sharesChange Vs. Previous Month+526.69%Dollar Volume Sold Short$764.10 thousandShort Interest Ratio1.2 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares15,210,000 sharesFloat Size13,630,000 sharesShort Percent of Float15.33%Today's Trading Volume3,599,183 sharesAverage Trading Volume3,957,561 sharesToday's Volume Vs. Average91% Short Selling VYNE Therapeutics? Sign up to receive the latest short interest report for VYNE Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVYNE Short Interest Over TimeVYNE Days to Cover Over TimeVYNE Percentage of Float Shorted Over Time VYNE Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/20252,090,000 shares $764.10 thousand +526.7%15.3%1.2 $0.37 7/15/2025333,500 shares $430.22 thousand -33.5%2.5%0.5 $1.29 6/30/2025501,300 shares $827.15 thousand +45.6%3.5%0.6 $1.65 6/15/2025344,200 shares $309.57 thousand +2.9%2.5%0.9 $0.90 5/31/2025334,600 shares $322.89 thousand +46.8%2.5%1.4 $0.97 5/15/2025227,900 shares $284.88 thousand +4.8%1.7%1.1 $1.25 4/30/2025217,500 shares $289.28 thousand +13.8%1.6%1.3 $1.33 4/15/2025191,100 shares $347.80 thousand +40.8%1.5%1.3 $1.82 3/31/2025135,700 shares $214.41 thousand -9.8%1.1%1 $1.58 3/15/2025150,500 shares $278.43 thousand +21.6%1.2%1.3 $1.85 Get the Latest News and Ratings for VYNE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/28/2025123,800 shares $311.98 thousand -11.4%1.0%1.2 $2.52 2/15/2025139,800 shares $345.31 thousand +13.5%1.1%1.4 $2.47 1/31/2025123,200 shares $289.52 thousand +9.7%1.0%1.1 $2.35 1/15/2025112,300 shares $309.95 thousand +82.9%0.9%1 $2.76 12/31/202461,400 shares $205.69 thousand -1.6%0.5%0.5 $3.35 12/15/202462,400 shares $159.74 thousand -3.0%0.5%0.7 $2.56 11/30/202464,300 shares $190.33 thousand -37.1%0.5%0.8 $2.96 11/15/2024102,200 shares $275.94 thousand +23.7%0.8%1.3 $2.70 10/31/202482,600 shares $224.67 thousand +65.2%0.7%1.2 $2.72 10/15/202450,000 shares $100 thousand -14.1%0.4%1 $2.00 9/30/202458,200 shares $109.42 thousand +75.8%0.5%1.3 $1.88 9/15/202433,100 shares $60.90 thousand -28.8%0.3%0.7 $1.84 8/31/202446,500 shares $84.63 thousand -20.0%0.4%0.9 $1.82 8/15/202458,100 shares $108.07 thousand -13.0%0.5%1.1 $1.86 7/31/202466,800 shares $126.92 thousand +8.1%0.5%1.3 $1.90 7/15/202461,800 shares $139.05 thousand +10.6%0.5%1.1 $2.25 6/30/202455,900 shares $110.12 thousand -10.9%0.5%1 $1.97 6/15/202462,700 shares $144.21 thousand +22.2%0.5%0.7 $2.30 5/31/202451,300 shares $130.30 thousand -10.6%0.4%0.6 $2.54 5/15/202457,400 shares $160.72 thousand -30.0%0.5%0.6 $2.80 4/30/202482,000 shares $206.64 thousand -15.3%0.7%0.8 $2.52 4/15/202496,800 shares $248.78 thousand +13.1%0.8%0.9 $2.57 3/31/202485,600 shares $262.79 thousand +590.3%0.7%0.7 $3.07 3/15/202412,400 shares $24.92 thousand -63.4%0.1%0.1 $2.01 2/29/202433,900 shares $75.60 thousand -5.3%0.3%0.3 $2.23 2/15/202435,800 shares $77.33 thousand -31.8%0.3%0.4 $2.16 1/31/202452,500 shares $89.78 thousand -40.3%0.4%0.5 $1.71 1/15/202488,000 shares $181.28 thousand No Change0.7%0.2 $2.06 12/31/202388,000 shares $205.04 thousand +1,157.1%N/A0.2 $2.33 12/15/20237,000 shares $19.18 thousand -94.4%0.1%0 $2.74Utah’s New Oil Find (Ad)The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.Find out why this could be the most lucrative "underground" energy story in America 11/30/2023124,800 shares $413.09 thousand -15.0%1.0%0.4 $3.31 11/15/2023146,800 shares $604.82 thousand +150.9%1.2%0.4 $4.12 10/31/202358,500 shares $178.43 thousand +11.6%1.9%0.2 $3.05 10/15/202352,400 shares $144.10 thousand -7.6%1.7%3.3 $2.75 9/30/202356,700 shares $229.07 thousand -8.1%1.8%3.5 $4.04 9/15/202361,700 shares $237.55 thousand -0.2%2.0%4.1 $3.85 8/31/202361,800 shares $268.83 thousand -19.7%2.0%3.7 $4.35 8/15/202377,000 shares $373.45 thousand +13.1%2.4%3.7 $4.85 7/31/202368,100 shares $316.67 thousand +3.8%2.2%2 $4.65 7/15/202365,600 shares $276.83 thousand -6.0%2.1%0.7 $4.22 6/30/202369,800 shares $286.18 thousand -5.6%2.2%0.1 $4.10 6/15/202373,900 shares $352.28 thousand +13.7%2.4%0.1 $4.77 5/31/202365,000 shares $408.85 thousand -29.3%2.1%0.1 $6.29 5/15/202391,900 shares $705.79 thousand -55.6%2.9%0.1 $7.68 4/30/2023206,800 shares $1.09 million +119.1%6.6%0.3 $5.26 4/15/202394,400 shares $256.77 thousand -3.9%3.0%0.1 $2.72 3/31/202398,200 shares $302.46 thousand +30.2%3.1%1.7 $3.08 3/15/202375,400 shares $192.27 thousand +38.1%2.3%1 $2.55 2/28/202354,600 shares $182.09 thousand -2.5%1.7%0.8 $3.34 2/15/202356,000 shares $196.56 thousand -94.6%1.8%0.8 $3.51 1/31/20231,030,000 shares $267.80 thousand -29.0%N/A0.8 $0.26 1/15/20231,450,000 shares $388.31 thousand +105.2%N/A1.2 $0.27 12/30/2022706,800 shares $106.02 thousand -7.4%N/A0.6 $0.15 12/15/2022763,400 shares $129.47 thousand -4.3%N/A3.5 $0.17 11/30/2022797,700 shares $185.55 thousand +3.5%N/A4.3 $0.23 11/15/2022770,600 shares $189.30 thousand -3.6%N/A4.3 $0.25 10/31/2022799,300 shares $204.30 thousand +3.2%N/A2.7 $0.26 10/15/2022774,400 shares $187.79 thousand +0.0%N/A2.6 $0.24 9/30/2022774,200 shares $172.72 thousand -22.4%N/A2.6 $0.22 9/15/2022997,900 shares $282.41 thousand +48.9%N/A3.1 $0.28 8/31/2022670,200 shares $209.97 thousand -6.0%N/A1.9 $0.31 8/15/2022713,200 shares $228.22 thousand -4.9%N/A1.9 $0.32 7/31/2022750,300 shares $324.20 thousand -15.5%N/A2.5 $0.43 7/15/2022887,400 shares $399.33 thousand -22.8%N/A2.6 $0.45 6/30/20221,150,000 shares $447.35 thousand -9.5%N/A2 $0.39 6/15/20221,270,000 shares $660.40 thousand +5.0%N/A2 $0.52 5/31/20221,210,000 shares $492.95 thousand -11.7%N/A1.8 $0.41 5/15/20221,370,000 shares $545.26 thousand -12.7%N/A2 $0.40 4/30/20221,570,000 shares $659.40 thousand +8.3%N/A2.1 $0.42 4/15/20221,450,000 shares $767.05 thousand +57.0%N/A1.7 $0.53 3/31/2022923,800 shares $600.56 thousand -19.0%N/A0.8 $0.65 3/15/20221,140,000 shares $638.40 thousand -22.5%N/A1 $0.56 2/28/20221,470,000 shares $796.74 thousand -6.4%N/A0.5 $0.54 2/15/20221,570,000 shares $893.49 thousand -23.4%N/A0.6 $0.57 1/31/20222,050,000 shares $1.27 million +12.6%N/A0.7 $0.62 1/15/20221,820,000 shares $1.25 million -12.5%N/A0.7 $0.69 12/31/20212,080,000 shares $2.12 million -34.0%N/A0.9 $1.02 12/15/20213,150,000 shares $3.59 million +283.4%N/A1.3 $1.14 11/30/2021821,600 shares $846.25 thousand -11.7%N/A0.6 $1.03 11/15/2021930,900 shares $1.19 million +5.5%N/A1.3 $1.28Utah’s New Oil Find (Ad)The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.Find out why this could be the most lucrative "underground" energy story in America 10/29/2021882,000 shares $1.18 million +1.5%1.7%1 $1.34 10/15/2021869,400 shares $1.06 million -9.6%1.7%1 $1.22 9/30/2021962,100 shares $1.34 million -23.0%1.9%1.3 $1.39 9/15/20211,250,000 shares $1.85 million -11.4%2.5%1.5 $1.48 8/31/20211,410,000 shares $2.40 million -50.4%2.8%1.6 $1.70 8/13/20212,840,000 shares $5.06 million -6.6%5.6%3.2 $1.78 7/30/20213,040,000 shares $8.21 million +7.8%6.0%4.1 $2.70 7/15/20212,820,000 shares $7.76 million +9.7%5.6%3.2 $2.75 6/30/20212,570,000 shares $9.02 million -35.6%5.1%2.8 $3.51 6/15/20213,990,000 shares $14.52 million -1.2%7.9%4.6 $3.64 5/28/20214,040,000 shares $15.96 million -7.3%8.0%4.6 $3.95 5/14/20214,360,000 shares $14.13 million +15.7%8.6%4.4 $3.24 4/30/20213,770,000 shares $19.34 million +13.2%7.5%2.5 $5.13 4/15/20213,330,000 shares $18.78 million -0.9%6.6%1.4 $5.64 3/31/20213,360,000 shares $22.14 million +14.7%6.7%1.4 $6.59 3/15/20212,930,000 shares $21.65 million +7.7%5.8%1.3 $7.39 2/26/20212,720,000 shares $21.46 million -71.8%5.4%1.2 $7.89 2/12/20219,660,000 shares $102.78 million -7.9%19.7%4.8 $10.64 1/29/202110,490,000 shares $93.57 million +15.2%5.8%1.6 $8.92 1/15/20219,110,000 shares $60.13 million No Change5.7%2.4 $6.60 VYNE Short Interest - Frequently Asked Questions What is VYNE Therapeutics' current short interest? Short interest is the volume of VYNE Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 31st, investors have sold 2,090,000 shares of VYNE short. 15.33% of VYNE Therapeutics' shares are currently sold short. Learn More on VYNE Therapeutics' current short interest. What is a good short interest ratio for VYNE Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VYNE shares currently have a short interest ratio of 1.0. Learn More on VYNE Therapeutics's short interest ratio. What is a good short interest percentage for VYNE Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 15.33% of VYNE Therapeutics' floating shares are currently sold short. Is VYNE Therapeutics' short interest increasing or decreasing? VYNE Therapeutics saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 2,090,000 shares, an increase of 526.7% from the previous total of 333,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is VYNE Therapeutics' float size? VYNE Therapeutics currently has issued a total of 15,210,000 shares. Some of VYNE Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. VYNE Therapeutics currently has a public float of 13,630,000 shares. How does VYNE Therapeutics' short interest compare to its competitors? 15.33% of VYNE Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to VYNE Therapeutics: Elevation Oncology, Inc. (3.92%), Aytu BioPharma Inc. (10.84%), BioAtla, Inc. (7.56%), Adaptimmune Therapeutics PLC (3.61%), Moleculin Biotech, Inc. (14.73%), CASI Pharmaceuticals Inc. (0.93%), Q32 Bio Inc. (9.28%), Finch Therapeutics Group, Inc. (0.01%), Passage Bio, Inc. (3.21%), Reviva Pharmaceuticals Holdings, Inc. (34.18%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), MicroStrategy Incorporated ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short VYNE Therapeutics stock? Short selling VYNE is an investing strategy that aims to generate trading profit from VYNE Therapeutics as its price is falling. VYNE shares are trading up $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against VYNE Therapeutics? A short squeeze for VYNE Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VYNE, which in turn drives the price of the stock up even further. How often is VYNE Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VYNE, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies Elevation Oncology Short Interest Data Aytu BioPharma Short Interest Data BioAtla Short Interest Data Adaptimmune Therapeutics Short Interest Data Moleculin Biotech Short Interest Data CASI Pharmaceuticals Short Interest Data Q32 Bio Short Interest Data Finch Therapeutics Group Short Interest Data Passage Bio Short Interest Data Reviva Pharmaceuticals Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VYNE) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access